SUMMARY, EXPLANATION AND LIMITATIONS:
Pax-5 (Paired Box Protein 5), also known as BSAP (B-Cell Specific Activator Protein), is a nuclear marker for Blymphocytes. The protein is detectable already in pro- and pre-B-cells as well as in mature B-cells. Its expression is down-regulated in plasma cells. Pax-5 affects the expression of certain B-cell specific markers, such as CD19 and CD20. Recent investigations have shown that detection of Pax-5 has in some cases a higher specificity and sensitivity for Bcells than detection of CD20 or CD79a. This holds true e.g. for DLBCL (diffuse B-cell large cell lymphomas). Additionally, new therapies targeting CD20 are expected to lead to increased numbers of CD20 negative B cell lymphoma and leukaemia after therapy (Clarke LE et al.). In these cases alternative markers like Pax-5 can be helpful. It was observed, that this anti-Pax-5 antibody can bind to precursor erythrocytes in bone marrow.
Immunogen: Synthetic peptide according the C-terminus of the human Pax-5 proteins.
Staining pattern: Nuclear.
Positive control: Tissue sample from tonsil.
This antibody is designed for the specific localization of human Pax-5 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
This antibody is useful in identifying pre-B cells, pro and mature, as well as the classification of lymphomas. As part of a panel of antibodies, is also useful to identify classic Hodgkin lymphoma versus anaplastic large cell lymphoma.